C3肾小球病:新型治疗范式
C3肾小球病(C3G)通过肾活检诊断,免疫荧光显示孤立或优势C3沉积,提示替代补体途径过度激活是肾小球损伤的关键驱动因素。随着多种补体靶向药物进入研发和临床试验,本文综述了C3G治疗范式的演变,先梳理非补体靶向治疗的有限疗效,再重点讨论针对补体级联不同组分的疾病特异性治疗研究进展。
要点
- C3G诊断依赖肾活检免疫荧光显示孤立或优势C3沉积。
- 替代补体途径过度激活是C3G肾小球损伤的关键驱动因素。
- 补体靶向药物正推动C3G向疾病特异性治疗范式转变。
核心结论
- C3G的治疗范式正从非补体靶向治疗向针对补体级联不同组分的疾病特异性治疗演变。
研究设计与样本
- 本文为综述,系统梳理C3G治疗范式的演变及补体靶向药物的研发与临床试验进展。
主要发现
- 非补体靶向治疗对C3G疗效有限。
- 针对补体级联不同组分的药物研发旨在提供疾病特异性治疗。
关键数值与推荐
- C3G诊断依据肾活检免疫荧光显示孤立或优势C3沉积。
临床怎么用
- 肾内科医生应关注补体靶向药物临床试验进展,为C3G患者探索疾病特异性治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
C3 glomerulopathy (C3G) is diagnosed by kidney biopsy, with immunofluorescence showing isolated or dominant C3 staining, indicating hyperactivity of the alternative complement pathway as the key driver of glomerular injury. Therefore, the lesion is defined by its complement-mediated pathogenesis as much as its histological pattern. As a bevy of complement-targeting agents are moving through development and clinical trials, we review the evolution in treatment paradigms for C3G. Here we survey the limited efficacy of noncomplement targeting therapy before focusing on the work being done on targeting various components of the complement cascade in aiming to provide disease-specific therapy.
引用
- Tarragon Estebanez B, Bomback AS. C3 Glomerulopathy: Novel Treatment Paradigms. Kidney Int Rep. 2023. PMID: 38481517. doi:10.1016/j.ekir.2023.12.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。